ClinicalTrials.gg
Status unknownNCT05449470ADFICE_ITUpdated Feb 2, 2023

A Clinical Decision Support System and Patient Portal for Preventing Medication-related Falls in Older Patients

An interventional study of CDSS and Patient Portal in Fall, Fall Injury and Fall Patients, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Status unknown at 10 sites in Netherlands. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Falls in older adults represents a growing public health challenge. The use of certain medication is recognized as an important modifiable risk factor for falls. Research indicates fall-risk increasing drug (FRID) deprescribing is effective in reducing falls but difficult to initiate and to sustain over longer periods of follow-up. A clinical decision support system (CDSS) and patient portal for communicating medication-related fall risk to fall clinic patients may improve joint medication management between patients and physicians and consequently reduce the incidence of injurious falls.

Read the detailed description

This study investigates the effectiveness and cost-effectiveness of the concurrent use of a CDSS and a patient portal for personalized FRID deprescribing, and will be assessed through a multicenter cluster-randomized controlled trial among new fall clinic patients, aged 65 years or older. The main study parameter is the time to first injurious fall. The primary objective of the ADFICE_IT study is to investigate the effects of a CDSS and accompanying patient portal for optimizing FRID deprescribing on injurious falls. This study has three secondary objectives. First, the effect of the CDSS and patient portal on a number of secondary outcomes will be investigated. Second, a process evaluation to evaluate the implementation of the CDSS and patient portal will be conducted. Third, the cost-effectiveness of the CDSS and patient portal will be investigated.

02

Conditions studied

  • Fall
  • Fall Injury
  • Fall Patients
  • Accidental Fall
  • Deprescriptions
  • Polypharmacy
  • Aged
  • Aged, 80 and Over

Keywords

  • fall prevention
  • fall-risk increasing drugs (FRIDs)
  • older out-clinic patients
  • injurious falls
  • prediction model
  • clinical decision support system
  • patient portal
  • Shared Decision Making (SDM)
  • medication withdrawal
03

In context

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 532 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of at least one fall in the past year;
  • A Mini-Mental State Examination (MMSE) score of 21 points or higher or equivalently a Montreal Cognitive Assessment (MOCA) Dutch score of 16 points or higher;
  • Use of at least one fall-risk increasing drug (FRID); and
  • Sufficient command of the Dutch language in speech and writing.

Exclusion criteria

Exclusion Criteria:

  • Active participation in another study;
  • Life expectancy of less than one year: and/or
  • Suffering from severe mobility impairment (i.e. bedridden, e.g. inability to walk short distances with assistance of a walking aid).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    CDSS and patient portal

    The intervention includes the combined use of the clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction and a patient portal.

    Device: CDSS · Device: Patient Portal

  • No intervention
    Care as usual

    Care as usual

Interventions

  • DeviceCDSS

    A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction

    Also known as: Clinical Decision Support System

  • DevicePatient Portal

    A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.

    Also known as: Valportaal

06

What researchers measure

Primary outcomes

  1. Time to first injurious fall

    This concerns the time to the first injurious fall. An injurious fall is defined as a fall resulting in wounds, bruises, sprains, cuts, medically recorded fractures, head or internal injury, requiring medical/health professional examination, accident and emergency treatment, or inpatient treatment.

    Time frame: 12 months

Secondary outcomes

  1. Number of injurious falls

    This concerns the total number of injuirous falls over the course of 12 months. An injurious fall is defined as a fall resulting in wounds, bruises, sprains, cuts, medically recorded fractures, head or internal injury, requiring medical/health professional examination, accident and emergency treatment, or inpatient treatment.

    Time frame: 12 months

  2. Total number of falls

    Total number of any fall (I.e. a fall that results in no injuries, or minor, moderate, or severe injuries)

    Time frame: 12 months

  3. Time to first fall resulting in any injuries

    I.e. a fall that results in minor, moderate, or severe injuries

    Time frame: 12 months

  4. Total number of falls resulting in any injuries

    I.e. a fall that results in minor, moderate, or severe injuries

    Time frame: 12 months

  5. Time to first non-injurious fall

    I.e. a fall that results in no injuries

    Time frame: 12 months

  6. EuroQol-5D-5L (EQ-5D-5L)

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). Furthermore, it includes a visual analogue scale (EQ-VAS) which provides a single global rating of self-perceived health and is scored on a 0 (worst health imaginable) to 100 (best health imaginable) scale.

    Time frame: at baseline, 3 months, 6 months, and 12 months

  7. The Older Persons and Informal Caregivers Minimum Data Set-Short Form (TOPICS-SF)

    Data as measured by the The Older Persons and Informal Caregivers Minimum Data Set-Short Form (TOPICS-SF) will be analysed based on the preference-weighted score, ranging from 1.90 to 9.78, with higher scores reflecting a better health status, as perceived by the respondent. The TOPICS - Short Form 2017 including Casemix forms were developed in collaboration with the Nederlandse Vereniging voor Klinische Geriatrie (NvKG - Dutch Association for Clinical Geriatrics) to use as a Patient Reported Outcome Measure (PROM) in the Dutch outpatient and clinical daily practice.

    Time frame: at baseline and 12 months

  8. iMTA Productivity Cost Questionnaire (iPCQ)

    Direct and indirect costs related to the intervention and care as usual will be assessed using the iMTA Productivity Cost Questionnaire (iPCQ).

    Time frame: at baseline, 3 months, 6 months, and 12 months

  9. iMTA Medical Consumption Questionnaire (iMCQ)

    The iMTA Medical Consumption Questionnaire (iMCQ) is an instrument for measuring medical consumption. The iMCQ includes questions related to frequently occurring contacts with health care providers.

    Time frame: at baseline, 3 months, 6 months, and 12 months

Other outcomes

  1. Feasibility assessed by number of CDSS and patient portal use

    To assess the feasibility of the intervention, the investigators will use data logged by the CDSS and patient portal to understand how (often) the CDSS and patient portal are used

    Time frame: 12 months

  2. Percentage of physicians attending the CDSS training via a questionnaire

    To assess the feasibility of the intervention, the investigators will look at the percentage of physicians who attended the CDSS training. More specifically, this will be measured by asking physicians whether they attended the CDSS training online, offline or not at all as part of the CDSS user satisfaction questionnaire.

    Time frame: 12 months

  3. Correlation of percentage of physicians attending the CDSS training and CDSS user satisfaction

    The correlation between the proportion of a department's staff members who did/did not participate in the CDSS training and user satisfaction regarding the CDSS will be assessed.

    Time frame: 12 months

  4. CDSS user satisfaction

    To assess the feasibility of the intervention, the investigators will study the satisfaction regarding the CDSS (i.e. physician evaluations of the CDSS). Agreement with satisfaction statements will be scored on a 7-point Likert scale (1= totally disagree; 7 = totally agree).

    Time frame: 12 months

  5. Technology Acceptance Model (TAM)

    The Technology Acceptance Model (TAM) is designed to measure the adoption of a new technology/system based on user attitudes. 6 items aim to measure Perceived Usefulness on a 7-point Likert scale (1=totally disagree; 7 = totally agree), and 6 items aim to measure Perceived Ease of Use on a 7-point Likert scale (1=totally disagree; 7 = totally agree). Intention to use is measured through 1 item on a 7-point Likert scale (1=totally disagree; 7 = totally agree)

    Time frame: at baseline

  6. Website Satisfaction Scale (WSS)

    The Website Satisfaction Scale (WSS) measures satisfaction with comprehensibility, satisfaction with attractiveness, and satisfaction with emotional support through 12 items, for each sub scale using a 7-point Likert response scale, ranging from 1 'totally disagree' to 7 'totally agree'.

    Time frame: at 3 months

  7. Observer OPTION Multiple Chronic Conditions (OPTION-MCC)

    Videotaped consultations will be coded on triadic decision making in older patients with multiple chronic conditions by using the Observer OPTION Multiple Chronic Conditions (OPTION-MCC) coding scheme. Six types of physicians', patients', and caregivers' behaviors are coded. Physicians' behavior is coded on a 5-point scale (0= The behavior is not observed; 4=The behavior is executed to a very high standard), patients' behavior is coded on a 3-point scale (0=No or minimal participation, e.g. only yes or no; 2=Active participation, answers questions and asks questions, brings in own ideas and shares perceptions), and informal caregivers' behavior is coded on a 3-point scale (0=No or minimal participation, e.g. only yes or no; 2=Active participation, answers questions and asks questions, brings in own ideas and shares perceptions)

    Time frame: 12 months

  8. Rate of adherence to new medication plan using pharmacy records

    To assess adherence to the medication advice, the investigators will compare a patient's new medication advice with their pharmacy records to determine whether a patient adheres to the new medication advice or whether they (eventually) change back to their old medication

    Time frame: 12 months

  9. Number of falls calendar entries

    To assess adherence to the medication advice, the investigators will compare the new medication advice with falls calender entries on medication use to determine whether a patient adheres to the new medication advice or whether they (eventually) change back to their old medication

    Time frame: 12 months

  10. iSHARE

    To evaluate how the intervention facilitates SDM, the investigators will use the iSHAREpatient and iSHAREphysician questionnaires. The iSHAREphysician consists of 16 items scored on a 6-point Likert scale (1= did not do this at all; 6 = completely did this). The iSHAREpatient consists of 16 items scored on a 6-point Likert scale (1= did not do this at all; 6 = completely did this). Dimension scores (range, 0-5) and a total score (the sum of the dimension scores; range, 0-30) for both iSHARE questionnaires will be calculated. The investigators will then apply a linear transformation to obtain a 0 to 100 total score ((score/30)\*100). Higher dimension and total scores indicate higher levels of SDM.

    Time frame: 12 months

  11. Decisional Conflict Scale (DCS; low literacy scale)

    To evaluate how the intervention facilitates SDM, the investigators will use the Decisional Conflict Scale (DCS; low literacy scale). This scale consists of 10 questions, scored on 3 response categories (yes, do not know, no).

    Time frame: at baseline

  12. Preparation for Decision-making scale (PrepDM)

    To evaluate how the intervention facilitates SDM, the investigators will use the Preparation for Decision-making scale (PrepDM). This scale consists of 10 items, scored on a 5-point Likert scale (1= not at all; 5 = a great deal)

    Time frame: at baseline

  13. Netherlands Patient Information Recall Questionnaire (NPIRQ)

    To evaluate how the intervention facilitates SDM, the investigators will use the Netherlands Patient Information Recall Questionnaire (NPIRQ). This questionnaire consists of open questions.

    Time frame: 12 months

07

Study locations

3 of 10 sites recruiting
  • Radboud universitair medisch centrum
    Nijmegen, Gelderland 6525 GA, Netherlands
    Not yet recruiting
  • Elisabeth-TweeSteden Ziekenhuis
    Tilburg, North Brabant 5042 AD, Netherlands
    Recruiting
  • Ziekenhuis Amstelland
    Amstelveen, North Holland 1186 AM, Netherlands
    Not yet recruiting
  • Amsterdam UMC, locatie VUmc
    Amsterdam, North Holland 1081 HV, Netherlands
    Recruiting
  • OLVG
    Amsterdam, North Holland 1091 AC, Netherlands
    Not yet recruiting
  • Amsterdam UMC, locatie AMC
    Amsterdam, North Holland 1105 AZ, Netherlands
    Recruiting
  • Spaarne Gasthuis
    Haarlem, North Holland 2035 RC, Netherlands
    Not yet recruiting
  • Medisch Centrum Leeuwarden
    Leeuwarden, Provincie Friesland 8934 AD, Netherlands
    Not yet recruiting
  • UMC Groningen
    Groningen, 9713 GZ, Netherlands
    Not yet recruiting
  • St. Antonius Ziekenhuis
    Utrecht, 3543 AZ, Netherlands
    Not yet recruiting
08

References and documents

Publications

  • Groos SS, de Wildt KK, van de Loo B, Linn AJ, Medlock S, Shaw KM, Herman EK, Seppala LJ, Ploegmakers KJ, van Schoor NM, van Weert JCM, van der Velde N. Development of the ADFICE_IT clinical decision support system to assist deprescribing of fall-risk increasing drugs: A user-centered design approach. PLoS One. 2024 Sep 5;19(9):e0297703. doi: 10.1371/journal.pone.0297703. eCollection 2024. PubMed 39236057 ↗
  • de Wildt KK, van de Loo B, Linn AJ, Medlock SK, Groos SS, Ploegmakers KJ, Seppala LJ, Bosmans JE, Abu-Hanna A, van Weert JCM, van Schoor NM, van der Velde N; ADFICE_IT study team. Effects of a clinical decision support system and patient portal for preventing medication-related falls in older fallers: Protocol of a cluster randomized controlled trial with embedded process and economic evaluations (ADFICE_IT). PLoS One. 2023 Sep 26;18(9):e0289385. doi: 10.1371/journal.pone.0289385. eCollection 2023. PubMed 37751429 ↗

Individual participant data

Plan to share: Undecided — Currently no plan

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05449470
Collaborators
VU University of Amsterdam
Responsible party
Prof. dr. Nathalie van der Velde (Full Professor Geriatric medicine (internal medicine), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Jul 8, 2022
Start date
Jul 7, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Feb 2, 2023

Study contacts

Kelly K de Wildt
Contact
k.k.dewildt@amsterdamumc.nl
+31615377082
Bob van de Loo
Contact
r.vandeloo@amsterdamumc.nl
Nathalie van der Velde, MD, PhD
principal investigator · Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Natasja M van Schoor, PhD
principal investigator · Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health, Amsterdam, the Netherlands
Annemiek J Linn, PhD
study director · Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, The Netherlands

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion